Ocugen (OCGN) vs Surrozen (SRZN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Surrozen (SRZN) has outperformed Ocugen (OCGN) over the past year, gaining 82.9% versus a loss of 43.2%. Over five years, SRZN leads with a -73.5% price change compared with -88.5% for OCGN. Ocugen is the larger company by market cap ($330.2 million vs $283.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCGN | SRZN |
|---|---|---|
| Share price | $0.9737 | $24.10 |
| Market cap | $330.19M | $283.20M |
| 1-day change | -2.63% | -4.18% |
| YTD return | -25.93% | +11.26% |
| 1-year return | -43.18% | +82.87% |
| 5-year return | -88.45% | -73.48% |
| EPS (TTM) | $-0.26 | $-39.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $37.83 |
| 52-week low | $0.97 | $11.39 |
| Distance from 52-week high | -64.27% | -36.31% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1149.87% | +100.87% |
| Average volume | 5.81M | 475.02K |
| Shares outstanding | 339.11M | 11.75M |
| Employees | 116 | 44 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SRZN has outperformed OCGN by 126.1 percentage points over the past year.
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees
About Surrozen
SRZN stock →Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 44 employees
OCGN vs SRZN FAQ
Which is bigger, Ocugen or Surrozen?
Ocugen (OCGN) is larger, with a market capitalization of $330.19M compared with $283.20M for Surrozen (SRZN).
Which stock has performed better over the past year, OCGN or SRZN?
SRZN returned +82.87% over the past 12 months, compared with -43.18% for OCGN (price return, excluding dividends). Past performance does not predict future results.
Are Ocugen and Surrozen in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.